Farmakoekonomikos institutas - Company finances
|
EUR
|
2019
From: 2019-01-30
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 56,100 | 113,704 | 140,500 | 240,000 | 223,500 | 234,600 | 142,000 |
| Profit before tax | 32,925 | 58,990 | 81,254 | 181,517 | 144,722 | 158,809 | 70,493 |
| Net profit | 32,925 | 55,569 | 76,471 | 171,729 | 135,906 | 149,556 | 65,012 |
| Equity | 32,935 | 55,579 | 77,966 | 173,224 | 137,401 | 151,051 | 116,063 |
| Liabilities | - | - | - | 10,181 | 15,112 | 23,763 | 16,131 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 36,505 | 59,712 | 83,333 | 183,405 | 152,513 | 174,814 | 132,194 |
| Total assets | 36,505 | 59,712 | 83,333 | 183,405 | 152,513 | 174,814 | 132,194 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 79,791 | 79,775 | 68,269 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +102.7% | +23.6% | +70.8% | -6.9% | +5.0% | -39.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 90.2% | 93.1% | 91.8% | 93.6% | 89.1% | 85.6% | 49.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 100.0% | 98.1% | 99.1% | 98.9% | 99.0% | 56.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 58.7% | 48.9% | 54.4% | 71.6% | 60.8% | 63.7% | 45.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 58.7% | 51.9% | 57.8% | 75.6% | 64.8% | 67.7% | 49.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 0.1 | 0.1 | 0.2 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Farmakoekonomikos institutas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-12-23 | 2022-12-31 | 1208.26 |
Farmakoekonomikos institutas - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-12-17 | 2024-12-19 | 0.3 |
| 2024-12-05 | 2024-12-16 | 78.37 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Farmakoekonomikos institutas, MB, company code 305005011, is a small partnership engaged in business and other management consultancy activities. In 2025, revenue fell to €142.0K from €234.6K in 2024 and €223.5K in 2023, representing a 39.5% year-on-year decline and a 36.5% decrease over two years. Net profit also moderated to €65.0K in 2025, compared with €149.6K in 2024 and €135.9K in 2023. The net profit margin narrowed to 45.8% from 63.7% in 2024 and 60.8% in 2023, but profitability remained solid. At the end of 2025, total assets stood at €132.2K, equity at €116.1K and liabilities at €16.1K, indicating a strong equity position and limited leverage. The equity ratio was 87.8%, debt-to-equity was 0.14, ROE was 56.0%, ROA was 49.2%, and asset turnover reached 1.07x. Overall, 2025 reflects a smaller but still profitable operating base supported by a robust balance sheet.